Latest Hire Adds FDA Expertise to Firm's Strong Health Policy Team
Washington, D.C. – February 4, 2011: BGR Government Affairs announced today that David W. Boyer, a
highly regarded health affairs policy advocate, will join the firm as a Vice President and Healthcare
Practice Co‐Director starting February 14, 2011. David will help lobby on behalf of the firm’s healthcare clients which include pharmaceutical companies, nursing homes, medical device manufacturers, dialysis providers and hospitals.
David served for the past two years as Senior Director, Federal Affairs, for the Pharmaceutical Research and Manufacturers of America (PhRMA) where he lobbied U.S. Senate Republicans on issues impacting the biopharmaceutical industry. David also led PhRMA’s Congressional education and advocacy strategy for the upcoming reauthorization of the Prescription Drug User Fee Act. His Executive Branch experience includes serving as a Special Assistant to the President for Legislative Affairs under President George W. Bush. In this capacity, David served as primary liaison between the White House and the U.S. Senate on health care, agriculture, education, budget, small business and labor issues.
"Since BGR’s inception, the firm’s health care lobbying practice at the state and federal levels has been a driving force in our growth. David will further enhance BGR’s expertise in helping clients achieve their goals," said Bob Wood, President of the bipartisan lobbying firm BGR Government Affairs.
David’s government experience also includes serving as Assistant Commissioner for Legislation at the Food and Drug Administration (FDA). Prior to the FDA, David served at the U.S. Department of Health and Human Services in the Office of the Assistant Secretary for Legislation as well as Special Assistant to then Secretary Tommy Thompson. In addition, David's experience includes serving as the Republican health care lobbyist for the Biotechnology Industry Organization (BIO) and as Political Director for Richard Burr's Senate campaign in 2004.
According to David, "Over the next few years, Congress will consider a number of issues that are critically important to the healthcare sector - healthcare reform implementation, spending/deficit reduction, slowing the growth of federal healthcare spending, and reauthorization of FDA’s crucial user fee programs, just to name a few. Considering the enormous challenges ahead, I am thrilled to bring my experience and contacts to help advance the interests of BGR’s clients."
For More Information/Interviews Contact:
Loren Monroe, Principal, BGR Group